TEJ-KOHLI-FOUNDATION
10.10.2019 08:02:07 CEST | Business Wire | Press release
On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently funding the clinical trials and development of a ‘liquid biosynthetic’ solution that could offer an accessible, scalable and affordable solution to corneal blindness that would be relevant to many of the 12 million people worldwide who suffer from this type of blindness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005535/en/
The thesis of the Tej Kohli Foundation is that humanitarian efforts the world over will be greatly advanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture fund by backing, incubating, acquiring and accelerating the development of technology solutions. Only successful projects secure further funding support, leaving the Foundation agile to back the projects that will have the greatest impact.
Blindness is heavily impacted by poverty. According to the WHO, 14 million of the 39 million people who are blind live in India. 12.7 million people are currently waiting for a cornea transplant, including 6 million in India. The Tej Kohli Foundation’s ‘Cornea Institute’ at the LV Prasad Eye Institute in Hyderabad already conducts thousands of corneal transplants every year using donor cornea, largely for free. The Foundation recently cured five brothers and sisters in the same family from Rajasthan who had all been suffering with long-term visual impairment.
But the limited supply of donor cornea and the need for invasive surgery means that worldwide less than 1 in 70 will receive a cornea transplant each year. Artificial cornea or keratoprotheses are expensive and can cost up to US$20,000. The Tej Kohli Foundation is backing the development of technological solutions, because ending corneal blindness will require an affordable, accessible and scalable solution that does not rely on transplantation.
The Tej Kohli Foundation previously backed methods of synthesising artificial cornea from yeast and peptides, but new advances mean it has switched this funding to the development of the liquid biosynthetic, which aims to work by causing the regeneration of corneal tissue. The pro-regeneration tissue replacement could avoid the need for expensive corneal grafting and be applied in less than thirty minutes to fill a perforation or to repair a corneal ulcer.
In July 2018 the Tej Kohli Foundation also made a $2m gift to Massachusetts Ear and Eye, a teaching hospital of Harvard Medical School, to fund innovation in research into nano-string and DNA-sequencing technologies for early diagnostics and prevention, as well as ‘GelCORE,’ an adhesive biomaterial for replacing corneal tissue.
Michael Macfarlane, spokesperson for the Tej Kohli Foundation:
“There are limits to the number of corneal transplants that can take place each year, especially in poor and remote rural areas. The Tej Kohli Foundation is a global focal point for scientists and others who are developing pioneering treatments in this field. Our mission is to work with a range of partners in our goal to eliminate corneal blindness by 2035.”
Tej Kohli, co-Founder of the Tej Kohli Foundation:
“Eliminating corneal blindness is what I am most passionate about. I favour a venture-led approach to philanthropy whereby we bring people together and provide the funding to accelerate the development of solutions that might bring us a step closer to ending corneal blindness. The way that we run our Foundation is directly aligned with how we manage our commercial ventures and investments, and this approach means we can drive greater progress from every pound or dollar or rupee that we spend on achieving our mission.”
Find out more about the Tej Kohli Foundation at: http://www.tejkohlifoundation.com
A video about a family of five siblings having their long-term visual impairment cured by the Tej Kohli Foundation is available to embed using this link: https://youtu.be/Pmcb9pRxOSs
A video interview with Wendy and Tej Kohli in which they talk about the work of the Tej Kohli Foundation is available to embed using this link: https://youtu.be/JgOO4Cs-jnw
A video about the Tej Kohli Cornea Program is available to embed using this link: https://youtu.be/2zUBtj6H7GM
A video about the Tej Kohli Cornea Institute is available to embed using this link: https://youtu.be/lkZmI8lkpm8
About The Tej Kohli Foundation
The Tej Kohli Foundation was launched by Wendy and Tej Kohli in 2005 as a focal point for their global philanthropic endeavours. The Foundation includes:
- Cornea Institute: which since 2016 has seen more than 180,000 outpatients and carried out 17,000+ cornea replacement surgeries, largely for free.
- Cornea Program: which funds innovation in research to cure corneal blindness at Mass. Eye and Ear, a teaching hospital of Harvard Medical School.
- Applied Research: which is engaged in the acquisition and development of new technologies that have the potential to substantially reduce corneal blindness globally.
- Impact Initiatives: which supports projects in underserved communities where direct interventions can have a sustained and positive impact upon individual lives.
http://www.tejkohlifoundation.com
About Tej Kohli
Tej Kohli is a London-based investor and entrepreneur with a well-publicized mission to cure corneal blindness worldwide by 2035. He first rose to success during the dotcom boom selling technology solutions and e-commerce payments software before becoming a real estate investor in technology hubs. He now focuses on high-impact investments into AI, robotics, biotech and genomics ventures. Tej Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 15:36:00 CEST | Press release
David Ogg appointed Vice Chairman and Brian Andreyko named CEO MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going o
Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 15:00:00 CEST | Press release
The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction TransactionsDebt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance t
rhode Announces Official Launch Date for Its Retail Expansion in Europe with Sephora31.8.2026 15:00:00 CEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), today announced its collection of high-performance, skin-focused products will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831869746/en/ rhode will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026 Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode remains the No.1 overall skincare
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
